SCHEMBL6352174

SCHEMBL6352174

NC(=O)c1nn(-c2ccc(S(N)(=O)=O)cc2)c2c1ccc1ccc(NS(=O)(=O)c3cccc(Br)c3)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 1/20 0.43
CA1 P00915 5/20 0.41
CA2 P00918 5/20 0.41
BRD4 O60885 1/20 0.41
CA9 Q16790 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CA4 P22748 1/20 0.40
MMP2 P08253 2/20 0.39
MMP9 P14780 2/20 0.39
HIF1A Q16665 1/20 0.39
PTPN2 P17706 1/20 0.38
PTPN1 P18031 1/20 0.38
PTPN5 P54829 1/20 0.38
PTGS2 P35354 2/20 0.38
MAP4K4 O95819 1/20 0.38
PAK4 O96013 1/20 0.38
PIM1 P11309 1/20 0.38
LTK P29376 1/20 0.38
KDR P35968 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6353535 0.90 MAPK1 (0.44) HSD17B2CA1CA2CA9MEN1
SCHEMBL6345855 0.90 PTGS2 (0.44) CA1CA2BRD4CA9MEN1
SCHEMBL6354591 0.87 CA2 (0.47) HSD17B2CA2HIF1APTPN2PTPN1
SCHEMBL6352252 0.86 PTGS2 (0.43) CA1CA2CA9CA4PTGS2
SCHEMBL6353488 0.85 ALDH1A1 (0.48) CA1CA2CA9MEN1KMT2A
SCHEMBL6345751 0.83 CA1 (0.44) CA1CA2CA9CA4PTGS2
SCHEMBL6341929 0.83 PTGS2 (0.43) CA1CA2CA9CA4PTGS2
SCHEMBL6344422 0.82 PTGS2 (0.42) CA1CA2BRD4CA9MEN1
SCHEMBL6355132 0.82 CA2 (0.42) CA1CA2CA9CA4PTGS2
SCHEMBL6342102 0.80 CA2 (0.48) CA1CA2CA9CA4PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1438293-A2 SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2004-07-21 EP claimed
US-20030125361-A1 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-07-03 US claimed
WO-2003027075-A2 SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2003-04-03 WO claimed
US-6849653-B2 1H-benzo(g)indazole compounds as anticarcinogenic agents and also treat arthritis PHARMACIA CORPORATION (US) 2005-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125361-A1 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation IRAK4, NLRP3, CXCL8 HSD17B2 2466/4885CA1 3893/4885CA2 4013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.